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SUMMARY Staphylococcus aureus is one of the most common pathogens of humans
and animals, where it frequently colonizes skin and mucosal membranes. It is of major
clinical importance as a nosocomial pathogen and causative agent of a wide array of
diseases. Multidrug-resistant strains have become increasingly prevalent and represent a
leading cause of morbidity and mortality. For this reason, novel strategies to combat
multidrug-resistant pathogens are urgently needed. Bacteriophage-derived enzymes, so-
called endolysins, and other peptidoglycan hydrolases with the ability to disrupt cell
walls represent possible alternatives to conventional antibiotics. These lytic enzymes
confer a high degree of host speciﬁcity and could potentially replace or be utilized in
combination with antibiotics, with the aim to speciﬁcally treat infections caused by
Gram-positive drug-resistant bacterial pathogens such as methicillin-resistant S. aureus.
LysK is one of the best-characterized endolysins with activity against multiple staphylo-
coccal species. Various approaches to further enhance the antibacterial efﬁcacy and ap-
plicability of endolysins have been demonstrated. These approaches include the con-
struction of recombinant endolysin derivatives and the development of novel delivery
strategies for various applications, such as the production of endolysins in lactic acid
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bacteria and their conjugation to nanoparticles. These novel strategies are a major focus
of this review.
KEYWORDS antibiotic resistance, endolysin, Staphylococcus aureus, probiotic
bacteria, nanoparticles, infectious diseases
INTRODUCTION
Staphylococcus aureus is a coccoid Gram-positive bacterium with a thick peptidogly-can layer (1), also known as a murein layer (Fig. 1). This murein layer consists of long
ionic polymers comprising the alternating amino sugars N-acetylglucosamine and
N-acetylmuramic acid that make up the glycan chains and peptide linkers connecting
these glycan chains to a three-dimensional network. In the case of S. aureus, these
peptide linkers consist of conserved stem peptides, which are interconnected through
ﬁve consecutive glycines, the so-called pentaglycine bridge (2). Another characteristic
feature of S. aureus peptidoglycan is O-acetylation at the C6-OH position of muramic
acid, rendering the bacterium resistant to lysozyme (3). Teichoic acids covalently linked
to the peptidoglycan function as regulators of cell growth, as phage receptors,
epitopes, for attracting cations, and as tools for pathogens to communicate with the
environment (1, 4).
S. aureus is known to be a part of the normal microﬂora. This bacterium resides
primarily on the nares, skin, and mucosal membranes of humans and animals and poses
no threat to the host species under normal circumstances (5). The colonization rate in
healthy adults is between 5 and 30%, and 10 to 20% of individuals exhibit permanent
colonization (6). Conversely, bacteria from healthy individuals can pose a risk of
transmission to the immunocompromised population, yielding detrimental effects on
those infected (7, 8). A variety of diseases can be caused by staphylococcal strains,
ranging from rather harmless localized skin infections to systemic infections upon the
entry of bacteria into the blood as well as acute and chronic infections of various organs
such as heart, bones, and lungs (9, 10). Sepsis, endocarditis, and toxic shock syndrome
are examples of life-threatening diseases caused by S. aureus (11). One of the critical risk
factors for the development of hospital-acquired (HA) and community-acquired (CA)
infections is S. aureus nasal carriage (12). Increased colonization rates have been
reported to lead to increased infection rates in the community and hospitals (13, 14).
ANTIBIOTIC RESISTANCE IN STAPHYLOCOCCUS AUREUS
Drug resistance in S. aureus can be acquired by different mechanisms, including
horizontal gene transfer via plasmids or other mobile genetic elements as well as
spontaneous mutations and selection (15, 16). This led to the emergence of multiple
strains that demonstrate resistance to one or a combination of antibiotics, such as
methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), and
multiple-drug-resistant S. aureus (MDRSA) (6). Over the past 20 years, there have been
ﬂuctuations in the prevalence of MRSA. Although overall rates of S. aureus infections
may have stabilized (8) and the prevalence of MRSA is slightly decreasing in some
Western countries, numbers are still alarmingly high on a worldwide scale. According
to U.S. and Dutch prevalence data, between 2 million and 53 million people are
conservatively estimated to carry MRSA worldwide (17).
Although comparison of epidemiological data has proven difﬁcult because of
differences in populations sampled and study designs, countries in North and South
America and Asia as well as Malta have been reported to have the highest MRSA rates,
exceeding 50%. Exceptionally high rates have been reported for Sri Lanka (86.5%),
South Korea (77.6%), Vietnam (74.1%), and Taiwan (65.0%). In contrast, India and the
Philippines have much lower rates of 22.6% and 38.1%, respectively. China, Australia,
African countries, and some Southern and Eastern European countries, such as Portu-
gal, Greece, Italy, and Romania, have intermediate rates ranging from 25 to 50%. MRSA
is generally less prevalent in many Western and Northern European countries, including
The Netherlands and Scandinavian countries (18).
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Mechanisms of Antibiotic Resistance
Beta-lactams, aminoglycosides, macrolides, tetracyclines, and glycopeptide antibi-
otics lyse or inhibit the growth of antibiotic-susceptible staphylococcal cells by disturb-
ing peptidoglycan synthesis or other vital functions of the cell. Penicillin and its
analogues act by recognizing and binding to penicillin-binding protein (PBP), thereby
inhibiting the cross-linking of pentaglycine chains (19). Macrolides, aminoglycosides,
and tetracyclines inhibit bacterial protein synthesis by binding to and inhibiting
ribosome function (20). By binding to the C-terminal D-alanyl–D-alanine of the pepti-
doglycan stem peptides, glycopeptides such as dalbavancin, oritavancin, teicoplanin,
telavancin, and vancomycin inhibit the transpeptidation of S. aureus peptidoglycan (21,
22). The rapid evolution of antibiotic-resistant microbes became apparent when resis-
tant strains of S. aureus emerged only 2 years after the discovery of penicillin in 1940
(23). A plasmid-encoded penicillinase (beta-lactamase) was responsible for this resistant
phenotype (24). The development of penicillinase-resistant methicillin was a response
to penicillin-resistant S. aureus in 1961, but certain strains showed resistance to
methicillin shortly thereafter, which led to the identiﬁcation of the methicillin resistance
gene mecA (25). By the genomic integration of this gene, S. aureus became resistant to
a broader range of beta-lactams. mecA encodes a mutated PBP, termed PBP2= (26),
which displays a low binding afﬁnity for beta-lactams, and as a consequence, pepti-
doglycan cross-linking is no longer affected by methicillin and related agents (27). After
methicillin, vancomycin emerged as the new antibiotic of last resort to treat the
infections by S. aureus (28). Vancomycin acts by binding to the terminal D-alanyl–D-
alanine moieties of N-acetylmuramic acid and N-acetylglucosamine peptide monomers,
thereby preventing peptidoglycan cross-linking and proper cell wall synthesis (29).
However, the overprescription of vancomycin led to either complete or partial disrup-
tion of vancomycin susceptibility of S. aureus strains, termed VRSA and vancomycin-
intermediate S. aureus (VISA), respectively (28). VISA was ﬁrst identiﬁed from a clinical
specimen in Japan in 1997 (30), while the ﬁrst VRSA strain was identiﬁed 5 years later
in the United States (31). Some isolates of VRSA were also resistant to beta-lactam
antibiotics, thus making these isolates multidrug resistant (31). VISA strains were since
identiﬁed to harbor mutations in several regulatory loci, i.e., the walRK, clpP, graRS, and
vraSR genes (32). The graRS and vraSR genes encode cell wall synthesis-regulatory
proteins that confer intermediate vancomycin resistance to VRSA strains (33). The
synthesis of the peptidoglycan is upregulated following mutations of the clpP, walRK,
vraSR, and graRS genes to produce an abnormally thick cell wall, thereby hindering
effective vancomycin penetration into the cell (21). Foreign genetic material containing
the vanA gene has also been revealed by genetic studies of VRSA; the presence of this
gene results in an alteration within the peptidoglycan, replacing the terminal D-alanyl–
D-alanine with D-alanyl–D-lactate, and consequently results in the abrogation of vanco-
mycin binding (31).
FIG 1 The cell wall structure of Gram-positive bacteria contains a thick layer of peptidoglycan that
resides beyond the cytoplasmic membrane.
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General Antibiotic Therapies for S. aureus
The antibiotic of choice for the treatment of S. aureus infections initially was
penicillin; however, penicillin resistance is extremely common in most countries (34). As
a result, a penicillinase-resistant -lactam antibiotic such as ﬂucloxacillin or oxacillin is
commonly used for ﬁrst-line therapy; these antibiotics have the same mechanism of
action as penicillin (35, 36). S. aureus strains that are methicillin resistant are also
resistant to other -lactam antibiotics, including penicillins (penicillin V, penicillin G,
ampicillin, oxacillin, carbenicillin, and amoxicillin), carbapenems (imipenem-cilastatin
[Primaxin]), cephalosporins (cephalothin), and monobactams (37).
Treatment of serious infections may utilize combination therapy with various anti-
biotics; however, because this strategy bears a high risk of damage to the kidneys, its
use is controversial (38). Therefore, aiming to combat MRSA, vancomycin, which is a
glycopeptide antibiotic, is commonly used. However, some treatment failures with
vancomycin have been reported, even in patients infected with vancomycin-
susceptible MRSA (39, 40). Linezolid, which belongs to the oxazolidinone class of drugs,
has been reported to have bacteriostatic activity against S. aureus. This antibiotic is
approved to treat complicated soft tissue and skin infections and also pneumonia in
children and adults. It has oral and parenteral formulations, and its oral bioavailability
is good (41), but S. aureus strains that are resistant to this antibiotic have been reported
as well (42).
The antibiotic daptomycin, belonging to the new class of cyclic lipopeptides, shows
activity against MRSA and methicillin-sensitive S. aureus (MSSA). This antibiotic is a
powerful bactericidal agent against S. aureus in vitro, and it has received approval for
the treatment of adults with complicated soft tissue and skin infections (43, 44).
Although some clinics have reported daptomycin resistance, the use of high concen-
trations of the antibiotic is still effective against S. aureus (45).
One promising class of broad-spectrum antibiotics is quinolones, assuming a critical
role in the treatment of hospital-acquired infections caused by strains that are resistant
to older antibacterial classes. For example, JNJ-Q2 and delaﬂoxacin, both of which are
quinolone derivatives, are now undergoing clinical trials (46). Fluoroquinolones, the
most commonly used subclass of quinolones in hospitals, can be effective against
MRSA (47). However, as for the above-mentioned antibiotics, resistance to ﬂuoroquino-
lones has also been observed in S. aureus (48), and this class of antibiotics is associated
with an increased risk of MRSA colonization, for which reason its use is discouraged (49).
There are additional antibacterial compounds that have entered clinical development,
but the majority of these candidate drugs have failed to reach the market (50).
Treatment Costs of Staphylococcus aureus Infections
Based on the drug susceptibility of the infecting S. aureus strain, the costs of
treatment can vary considerably. In the United States, a 6-month treatment regimen for
a methicillin-sensitive S. aureus infection may cost approximately $16,000; however,
costs for an otherwise identical MRSA infection treatment amount to nearly $36,000
(51). In addition to the increase in treatment costs, antimicrobial resistance has led to
prolonged hospital stays and increases in morbidity and mortality rates. There are
currently very few antibacterial agents present on the market for a number of common
antibiotic-resistant strains (52). As some strains show resistance to multiple common
antibiotics, there are few therapeutic options left to treat these multidrug-resistant
infections, and those options that are available tend to be expensive, toxic to the
patient, and/or less effective in treatment (53, 54).
BACTERIOPHAGE
History of Phage Therapy
Bacteriophages are considered the most abundant biological replicating entities on
earth (55). As viruses with the ability to infect and lyse bacteria, bacteriophages were
discovered separately by Frederick Twort and Félix d’Herelle (56, 57). Soon after this
discovery, d’Herelle realized the potential of using bacteriophages to treat human and
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animal bacterial infections (58). In 1919, a phage cocktail was prepared for the treat-
ment of a child suffering from dysentery, and after its safety was tested by adminis-
tering it to several healthy individuals, it was administered to the child. The boy
recovered after a single administration of the phage preparation. Three more patients
were treated in the same way, and all of them recovered soon after administration;
however, these results were not published (59). Phage therapy was soon abandoned by
western countries due to the discovery of antibiotics, but in the former Soviet Union,
bacteriophages were used from 1920 to 1940 for treating open wounds and intestinal
Salmonella and Shigella infections. Maintenance of phages in the body 3 to 10 days
after their administration was used as prophylaxis in regions where infections could
spread rapidly (60). In 1921, bacteriophages were used by Joseph Maisin and Richard
Bruynoghe for the treatment of staphylococcal skin infections, which resulted in
improvement within 24 to 48 h of administration (61). Several similar studies were
carried out, and phages were used to treat cholera and bubonic plague in several Asian
countries (62, 63). Besides phage therapy, bacteriophages have found a number of
applications in different ﬁelds, such as for sterilizing processed food, treating crops,
diagnosing infections, typing bacteria, and developing molecular biology assays (64–67).
However, there is still some reticence in using a biological replicating entity for human
phage therapy (68).
Bacteriophage-Derived Lytic Proteins
Many bacteriophages encode tail spike proteins that bind to receptors on the host
cell surface. The tail spikes often include enzymatic components (virion-associated
peptidoglycan hydrolases, also termed lytic structural proteins), which locally degrade
the peptidoglycan in the bacterial cell wall, thereby facilitating the injection of phage
DNA at the beginning of the infection process (58, 69). At the end of the phage lytic
cycle, progeny virions escape from the host cell by the help of another type of
phage-encoded peptidoglycan hydrolase, so-called endolysins. These enzymes, which
are not part of the phage virion, accumulate in the cytoplasm, from where they gain
access to the peptidoglycan through the action of a second phage protein, named
holin, in a highly time-controlled process (70). When the holin concentration reaches a
certain threshold, these initially monomeric transmembrane proteins are assembled
into pore-forming oligomers in the cytoplasmic membrane. As a result, the membrane
is depolarized, and the endolysins are allowed to diffuse through the membrane and
degrade their peptidoglycan target. Destabilization of the peptidoglycan sacculus in
combination with the internal turgor present in bacterial cells consequently results in
lysis and cell death (“lysis from within”). In the case of the exogenous application of
endolysins to Gram-positive pathogens, which do not have a protective outer mem-
brane, rapid and effective “lysis from without” is caused by these enzymes, which
makes endolysins interesting as potential antimicrobial agents (71, 72). The structure
and function as well as the application of phage endolysins as therapeutics are
discussed below.
ENDOLYSINS
Endolysin Structure and Function
Endolysins are categorized by their catalytic speciﬁcity, i.e., their target bonds
within the peptidoglycan substrate. The bonds between N-acetylmuramic acid and
N-acetylglucosamine in the sugar strands of the peptidoglycan are the targets for
glucosaminidases, muramidases, and lytic transglycosylases. The same bond is cleaved
by lytic transglycosylases and muramidases, but their cleavage mechanisms are differ-
ent (nonhydrolytic and hydrolytic, respectively). In contrast, endopeptidases cleave
various bonds within the peptide portion of the peptidoglycan, and amidases hydro-
lyze amide bonds that link the sugar and peptide moieties in the peptidoglycan layer
(71).
In the case of endolysins acting against Gram-negative bacteria, the catalytic
function is usually located within one single globular domain (73). In contrast, endo-
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lysins from a Gram-positive background typically show a modular design in which
catalytic function and speciﬁc cell wall recognition are separated in two or more
functional domains. In the simplest (and most frequent) case, they are composed of one
N-terminal enzymatically active domain (EAD) and one C-terminal cell wall-binding
domain (CBD), both of which are usually connected by a short linker region. However,
there are more complex architectures, featuring multiple EADs and/or CBDs in different
positions (65, 74–76). Most endolysins derived from staphylococcal phages, which are
described in more detail below, consist of a C-terminal SH3b-type CBD, an amidase in
a central location, and an N-terminal endopeptidase (Fig. 2) (77, 78). Also, endolysins
derived from a streptococcal phage, such as the B30 and lambda SA2 endolysins,
feature a dual-EAD architecture with muramidase and endopeptidase domains, in
addition to one or several CBDs (79). However, it has been shown for several dual-EAD
endolysins by deletion analysis and site-directed mutagenesis that one of these EADs
is virtually inactive, whereas the other one is dominant and exhibits high lytic activity
in a lysis-from-without scenario (74, 78). While the lytic activity of some endolysins
depends strictly on the presence of a CBD (77, 80, 81), this is not always the case. There
are other examples of endolysins whose activity is not compromised or is even
increased after the removal of the CBD (65, 74). The answer to the question of whether
a CBD is required or not has been suggested to depend on both the assay used to
determine the activity and the net charge of the EAD, with positively charged catalytic
domains being less dependent on a CBD (82). Among all endolysins described to date,
the lysin PlyC from streptococcal phage C1 is particularly unique, because its structure
is multimeric, consisting of two separate gene products, named PlyCA and PlyCB, of 50
kDa and 8 kDa, respectively. These gene products self-assemble into a complex
consisting of 1 PlyCA subunit and 8 PlyCB subunits (83). Although rare, there are a few
examples of modular endolysins from phages infecting Gram-negative bacteria, such as
the two-domain lysin KZ144 from a Pseudomonas phage (73).
Several studies have elucidated the crystal structures of both globular and modular
endolysins as well as individual functional domains thereof. Examples include the T7
lysin (84), the T4 lysin (85), the streptococcal phage lysins Cpl-1 (86) and PlyC (87), the
Bacillus phage lysins PlyL (88) and PlyB (89), the Listeria phage endolysin PlyPSA (90),
and the staphylococcal phage endolysin PlyGH15 (91). The crystal structure of Cpl-1 has
been investigated in both free and choline-bound states, suggesting that the choline-
binding CBD helps the N-terminal catalytic domain to be correctly positioned (86, 92).
It should be noted that the inherent ﬂexibility of modular endolysins (afforded by the
ﬂexible linker regions connecting the individual domains) often prevents the crystalli-
zation of full-length enzymes, for which reason the majority of reported endolysin
crystal structures comprise only single domains (65).
Endolysins as Potential Antimicrobials
As the treatment of bacterial infections proves to be increasingly difﬁcult with the
growing incidence of antibiotic-resistant strains, phage endolysins have been sug-
gested as promising alternative antibacterial therapeutics (93, 94, 228). These phage-
based enzymes have proven effective in various animal models of bacterial infection as
well as in the decolonization of mucosal membranes (summarized in Table 1).
Although endolysins with broad-range lytic activity have been identiﬁed (95), most
phage endolysins show near species speciﬁcity, and this is believed to be one of their
FIG 2 The modular structure of the LysK endolysin, consisting of 2 enzymatically active domains (CHAP
and amidase-2) and one bacterial SH3 (SH3b) cell wall-binding domain.
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most advantageous properties in this age of broad-range antibiotic resistance, by
avoiding selective pressure on commensal populations (65). Furthermore, the devel-
opment of resistance against endolysins is unlikely for several other reasons. Since the
phage and the host bacteria are coevolving, endolysins have evolved to bind to and
cleave highly conserved structures in the cell wall, the modiﬁcation of which is believed
to be detrimental to the host organism (96, 97). In addition, by being applied externally
and acting on the cell wall, without having to enter the bacterial cell, endolysins used
therapeutically avoid a majority of the possible resistance mechanisms (e.g., active
efﬂux from the cell or decreased membrane permeability) that play a role in resistance
to most conventional antibiotics (98, 99). Several endolysins also possess two catalytic
domains that hydrolyze different bonds in the peptidoglycan, which is also believed to
further reduce the chance of resistance development (1).
Finally, to enhance their therapeutic activity and to avoid the development of
resistance, multiple endolysins may be used in combination with antibiotics to treat
bacterial infections (1, 100). Synergistic effects among endolysins and between endo-
lysins and other antimicrobial agents have been reported (101–103). Other topics
related to the systemic application of endolysins, such as immunogenicity, toxicity, and
serum half-life, have been discussed elsewhere (65) and are not a focus of this review.
Engineering of Endolysins
The modular structure of endolysins provides a unique opportunity for protein
engineering in order to modify bacteriolytic activity, speciﬁcity, solubility, and other
physicochemical properties of these enzymes. One prime example of an engineered
enzyme with increased lytic activity is Ply187AN-KSH3b, a fusion of the endopeptidase
domain of the staphylococcal Ply187 lysin (Ply187AN) with the SH3b CBD of another
staphylococcal phage endolysin, LysK. The fusion construct displayed 10-fold-higher
staphylolytic than that of Ply187AN and was also more active than LysK in multiple
activity assays (104). Similarly, the chimeric enzyme ClyH has been created by the fusion
of a non-SH3b CBD from phiNM3, another S. aureus phage, with the endopeptidase
domain of Ply187, resulting in a 14-fold improvement in staphylolytic activity against
the tested strains. In addition, a broader spectrum of activity has been shown for ClyH,
including some staphylococcal strains that were not susceptible to native Ply187 (105).
Changes in speciﬁcity, such as an expansion of the lytic spectrum of an endolysin, can
be achieved by the exchange or addition of CBDs outside the native endolysin’s
serovar, species, or even genus speciﬁcity. Fusion of the endopeptidase domain of the
streptococcal LambdaSa2 phage endolysin with the SH3b CBDs from either the staph-
ylococcal phage endolysin LysK or lysostaphin drastically increased the staphylolytic
activity of the chimeric enzyme, while the parental streptolytic activity was maintained
(74, 106). The peptidoglycan hydrolase lysostaphin is a bacteriocin produced by S.
simulans that exhibits lytic activity against S. aureus (107). It features a modular
architecture similar to that of a bacteriophage endolysin, consisting of an N-terminal
catalytic domain and a C-terminal binding module. However, as opposed to endolysins,
lysostaphin targets the weakly conserved pentaglycine bridge of staphylococcal pep-
tidoglycan. Consequently, mutant strains featuring modiﬁcations within this portion of
the peptidoglycan and showing resistance to lysostaphin have been reported (108). For
this reason, it is not recommended that lysostaphin be used as a single antimicrobial
agent. However, combined applications with endolysin-derived proteins, which exploit
synergistic effects due to the different peptidoglycan cleavage sites of these enzymes,
have been reported and may represent a feasible strategy to decrease the chance of
resistance (102, 109). Furthermore, components of lysostaphin have been used for the
construction of chimeric peptidoglycan hydrolases (74, 109). The spectrum of speciﬁcity
of an enzyme can also be extended by a combination of two heterologous CBDs; this
has been shown by fusions of CBDs from Listeria phage endolysins with different
binding speciﬁcities that were ﬂuorescently tagged (110). Although the full lytic activity
of most endolysins depends on a CBD, there are various examples where the deletion
of a binding module resulted in enzymes with advantageous properties. When the CBD
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of the Bacillus anthracis prophage endolysin PlyL was deleted, the species speciﬁcity of
the parental enzyme was abolished, and its lytic activity was broadened to include a
wider spectrum of Bacillus species (88). In some cases, the removal of the CBD may even
increase endolysin potency. A truncated version of the Listeria phage endolysin Ply511
lacking a part of its CBD caused enhanced lysis zones compared to those with the
full-length parental enzyme in a soft agar overlay assay, which was attributed to a more
efﬁcient diffusion of the truncated construct through this semisolid matrix (111).
Similarly, truncation of the Clostridium difﬁcile phage endolysin CD27L to its N-terminal
domain (i.e., removal of its putative CBD) improved bacteriolytic activity and led to a
broadened lytic range of the deletion construct (112). Besides CBDs, the removal of
low-activity EADs may also improve the potency of an enzyme. The streptococcal
prophage LambdaSa2 endolysin contains two enzymatically active domains, a
C-terminal glycosidase that is poorly active and a highly active endopeptidase, in
addition to 2 centrally located Cpl-7 CBDs (113). The removal of the entire glycosidase
domain while retaining the CBDs led to an increased streptolytic activity of the
truncated enzyme compared to that of the parental endolysin (106). Another signiﬁcant
report recently described the construction of artiﬁcial staphylococcal peptidoglycan
hydrolases that combine three unique catalytic activities into single fusion proteins,
thereby effectively avoiding the development of resistant strains. Additional modiﬁca-
tion of these constructs with so-called protein transduction domains enhanced their
efﬁcacy against staphylococcal bioﬁlms and rendered them active against intracellular
staphylococci, as demonstrated in cultured mammary gland epithelial cells and a
mastitis mouse model (114). Besides the above-mentioned examples, molecular engi-
neering of endolysins led to constructs with an increased binding afﬁnity for the cell
wall (110), enhanced solubility (115), and an altered ionic strength optimum (110).
Endolysins with Activity against S. aureus
In the light of the above-mentioned resistance problem, S. aureus has become a
prime target for endolysin technology in recent years. Numerous studies describing
cloning, recombinant production, and characterization of native and engineered staph-
ylococcal peptidoglycan hydrolases in vitro and in animal models have been reported
during the past decade (65, 116).
The vast majority of these enzymes feature a unique 3-domain architecture, with
two EADs (one at the N terminus and a second one located centrally) and one
C-terminal SH3b-type CBD (Fig. 2). In most cases, the N-terminal EAD is a cysteine-,
histidine-dependent amidohydrolase/peptidase (CHAP), which cleaves the bond be-
tween D-Ala of the stem peptide and the pentaglycine bridge of the staphylococcal
peptidoglycan. The centrally located EAD displays amidase activity (amidase 2 or
amidase 3), cutting between the sugar strands and the stem peptide (78, 100, 117). The
SH3b domain is known to require an intact pentaglycine bridge for full binding activity,
which has been shown for the SH3b-like cell wall-targeting domain of the bacteriocin
lysostaphin (118). There are exceptions to this conserved architecture, such as the
2638A endolysin, which harbors an M23 endopeptidase domain instead of a CHAP
domain at its N terminus (119), as well as the P68 (115) and PlyGRCS (120) endolysins,
which feature 2-domain architectures. A few staphylococcal endolysins containing a
CBD unrelated to the common SH3b domain have been reported as well (121). For
most of the dual-EAD staphylococcal endolysins, lytic activity relies mostly on the
N-terminal CHAP endopeptidase domain (116, 122, 123), whereas the amidase domain
is virtually inactive when applied externally. One exception is the 2638A endolysin,
which features a highly active amidase domain (119).
Despite the highly similar modular design of the SH3b-containing enzymes, which
form by far the largest subgroup among the staphylococcal phage endolysins, they can
differ considerably at the amino acid sequence level. Becker et al. reported that these
proteins fall into 5 homology groups that show more than 90% sequence identity
within each group but less than 50% identity between groups. Six “stand-alone”
proteins could not be assigned to any of the groups. It is noteworthy that SH3b
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domains share the highest degree of conservation between the different groups and
stand-alone enzymes (74). The remarkable diversity found among this group of endo-
lysins at the sequence level is also reﬂected in the diverse enzymatic and antibacterial
properties of these enzymes. This became apparent when representative peptidogly-
can hydrolases from each of the above-mentioned homology groups were compara-
tively characterized (78). The 9 investigated enzymes (8 phage endolysins and the
bacteriocin lysostaphin) differed in their lytic activities against live S. aureus cells, their
optimum ionic strengths, their spectra of susceptible strains, and their efﬁcacies against
S. aureus bioﬁlms. The endolysin with the highest staphylolytic activity in this study was
LysK, which is derived from S. aureus phage K (124) and, at the same time, is one of the
best-characterized staphylococcal peptidoglycan hydrolases described to date. There-
fore, a separate section of this review is dedicated to LysK and its close homologues.
The ﬁrst staphylococcal phage endolysin tested in animal models was MV-L, which
is derived from phage MR11 and is able to kill various strains of S. aureus, including
VISA, MRSA, and VRSA variants. Conversely, MV-L is harmless to several other commen-
sal species that have been tested, such as Staphylococcus epidermidis, which is an
inhabitant of skin and mucus membranes that is able to competitively inhibit S. aureus
colonization (125). The nasal cavity in humans and animals is considered a primary site
of colonization by S. aureus. Intranasal treatment using MV-L was shown to effectively
eliminate S. aureus from artiﬁcially inoculated nares of mice (125). Nasal decolonization
ability has since also been demonstrated for engineered endolysin constructs such as
ClyS, a fusion protein consisting of the CHAP domain of the phage Twort endolysin and
the non-SH3b CBD of the phiNM3 endolysin. This chimera effectively decreased the
numbers of bacteria of an MRSA strain by 2 logs within 1 h, 24 h after inoculation in the
nasal passage (121). When applied in a murine skin infection model, a topical ointment
containing ClyS was demonstrated to be more effective than mupirocin, the commonly
prescribed antibiotic for topical application against S. aureus infections (126). Besides
nasal decolonization and topical applications on the skin, some staphylococcal endo-
lysins have also been shown to be effective against systemic S. aureus infections in
animal models. The survival of mice intraperitoneally infected with MRSA was improved
by 100% after a single 0.05-mg (2-mg/kg of body weight) intraperitoneal injection of
MV-L within 30 min after infection. However, when the same treatment was delayed by
1 h, mouse survival decreased by 40% or more when the treatment was further
postponed. In addition, MV-L was not able to eradicate all S. aureus bacteria from the
bloodstream (125).
More recently, the above-mentioned 9 unique peptidoglycan hydrolases were
compared for their efﬁcacies at rescuing mice from MRSA-induced bacteremia, with the
antibiotics vancomycin and oxacillin being used as controls (78). Mice were infected
intraperitoneally with MRSA together with an immunosuppressant. A total of 0.2 mg of
the enzymes (8 mg/kg) was administered via the same route 30 min later. Within 2
days, 75% of the infected and buffer-treated control mice died in this model. In
contrast, the endolysins phi11, LysK, 80, WMY, and 2638A were able to save 100% of
the mice, similarly to vancomycin and lysostaphin. Mice treated with these agents
temporarily developed clinical signs indicative of slight to moderate illness but com-
pletely recovered within 40 h postinfection. The endolysins phiSH2 and Twort rescued
only about 60% of the animals, while no protection was offered by the endolysin P68,
likely due to solubility issues (78).
Not only do endolysins hold promise as individually applied antibacterials, they also
have been reported to act synergistically when used in combination with each other
(i.e., two endolysins with different cleavage speciﬁcities) or with other antimicrobial
agents (127). The efﬁcacy of less efﬁcient or overused antibiotics can even be revived
by utilizing a combination of endolysins and antibiotics. For instance, intraperitoneal
administration of the fusion enzyme ClyS alone (0.96 mg [38.4 mg/kg]) increased
survival rates of MRSA-infected mice to 88% (121). However, when used in combination
with 100 g of oxacillin (a dose that, when individually administered, saved only 40%
of the animals), a similar efﬁcacy (80% survival) could be achieved with a reduced
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dose of ClyS of only 0.17 mg (6.8 mg/kg). This synergistic effect has been attributed
to the enhanced production of staphylococcal autolysins in the presence of oxacillin, an
inhibitor of peptidoglycan cross-linking. These autolytic enzymes may be responsible
for the observed synergy (121).
While the above-mentioned intraperitoneal infection and treatment studies may be
valid as important ﬁrst steps toward evaluating the in vivo efﬁcacy of endolysins, they
inadequately model localized infections such as endocarditis or osteomyelitis, which
involve deeper tissue penetration and the formation of abscesses (6). However, there
are a few studies that have also described the efﬁcacy of (engineered) endolysins in
more speciﬁc animal models of S. aureus infection. One example is the treatment of S.
aureus-induced endophthalmitis using the chimeric staphylococcal endolysin Ply187AN-
KSH3b, and also, the possibility of using other endolysins for the treatment of bacterial
eye infections has been reported (128, 129). S. aureus represents the leading cause of
this disease, which is characterized as a vision-threatening complication of ocular
trauma. Intravitreal injection of Ply187AN-KSH3b into the eyes of mice that had been
infected with S. aureus 6 to 12 h prior to treatment signiﬁcantly reduced bacterial
burdens in the eye and improved the clinical outcome, preserving retinal function.
Another example is the treatment of S. aureus-induced mammary gland infections
in a mouse model of bovine mastitis by chimeric phage endolysins in combination with
lysostaphin (101). The combination treatment reduced the numbers of intramammary
bacteria by 3 log units and markedly decreased inﬂammation, as measured by tumor
necrosis factor alpha concentrations and mammary gland wet weights.
Of note, a ﬁrst series of staphylococcal phage endolysin-based antibacterial prod-
ucts is already available on the market. These products include Staphefekt XDR.300, a
solution that is active against S. aureus (including MRSA) on human skin, and the
Gladskin series of skin care products for the treatment of various skin conditions with
an infectious component, such as acne, eczema, rosacea, and skin irritation. Both
products contain the active ingredient Staphefekt and are marketed by Micreos Human
Health BV (The Netherlands).
LysK AND ITS HOMOLOGUES
Structure, Function, and Physicochemical Properties
The endolysin LysK is derived from bacteriophage K, a virulent broad-range phage
from the family of Myoviridae whose genome length is 127,395 bp. Interestingly, LysK,
a 54-kDa protein of 495 amino acids, is encoded by two open reading frames inter-
rupted by an intron, and the mature endolysin is created from these two separated
parts through a splicing reaction (130). The modular architecture of LysK is that of a
typical 3-domain staphylococcal phage endolysin as described above, i.e., featuring a
CHAP domain, an amidase-2 domain, and an SH3b domain (Fig. 2) (130, 131, 229). The
cleavage sites of the CHAP and amidase-2 domains within the staphylococcal pepti-
doglycan (D-Ala–Gly endopeptidase and MurNAc–L-Ala amidase, respectively) have
been elucidated by mass spectrometry analysis of peptidoglycan digestion products
(100) and are identical to those reported for other staphylococcal phage endolysins (78,
117) (depicted in Fig. 3). While the mere presence of amidase activity was demonstrated
in those experiments, several studies predict that the midprotein amidase-2 domain
contributes little to the overall staphylolytic activity of the endolysin and is dispensable
in a lysis-from-without setting (131, 132).
Deletion studies showed that upon the removal of the amidase-2 and SH3 domains,
the construct retaining only the CHAP domain of LysK (termed CHAPK), comprising the
ﬁrst 165 amino acids, remained highly active and in addition showed increased
solubility compared to that of the parental full-length endolysin (131). Similarly, Becker
et al. generated a series of LysK deletion constructs and compared their in vitro
activities against S. aureus. As opposed to CHAPK, a CHAP-only construct produced in
that study (termed LysK221, comprising the ﬁrst 221 amino acids) retained only
marginal activity, possibly due to improper folding at the C-terminal end. However,
another deletion construct consisting of the CHAP and SH3b domains (i.e., a deletion
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of the amidase domain) exhibited staphylolytic activity similar to that of the full-length
enzyme (100). Another construct, named HY-133 (owned by Hyglos GmbH, Germany),
and its progenitor, PRF-119, which consist of the CHAP domain of LysK and the SH3b
domain of lysostaphin, were reported to display pronounced bactericidal activity
against multiple staphylococcal strains (132, 133).
Since LysK has been identiﬁed as an endolysin, researchers have conducted several
studies to determine its physicochemical properties. The biological stability of an
enzyme being considered for antimicrobial applications is particularly important, as
stability directly affects the efﬁcacy of the enzyme. The stability of LysK was found to
be increased 100-fold by the addition of sucrose, glycerol, or other low-molecular-
weight additives to the storage buffer. The addition of such low-molecular-weight
additives enables LysK to maintain 100% of its activity for up to a month at room
temperature, which is remarkable and very uncommon for most enzymes. The addition
of divalent cations such as Ca2 also increased the stability of LysK. At temperatures
over 40°C, a dramatic loss in stability was observed and attributed to secondary-
structure changes, as measured by circular dichroism spectroscopy (134). The same
group reported that LysK displayed increased stability in complexes with polycationic
polymers (poly-L-lysines [PLLs]) and block copolymers of these PLLs with polyethylene
glycol (135).
LysK was also one of the ﬁrst staphylococcal endolysins for which structural infor-
mation was available. Sanz-Gaitero et al. solved the crystal structure of CHAPK, which
showed a papain-like topology with the catalytic triad located inside a hydrophobic
cleft. Two metal ions were found to be associated with the structure: a structural
calcium ion and a zinc ion within the active site (122, 136). Shortly before that, the
structure of all three functional domains of the LysGH15 endolysin was reported (91).
Of note, LysGH15 is almost identical to LysK, differing in only 4 amino acids. Accord-
ingly, structural features described for the CHAP domain of LysGH15 are in agreement
with the CHAPK structure. In addition, those authors reported that the calcium ion-
binding site of the CHAP domain is located in a so-called “EF hand-like” motif in close
proximity to the active-site cleft and that the presence of the calcium ion is critical for
the lytic activity of the enzyme. The addition of calcium to the EDTA-inactivated CHAP
domain completely restored enzymatic activity, whereas other divalent metal cations
(including zinc) failed to do so. The amidase domain of LysGH15 was found to feature
a shallow groove on its surface, which would support the accommodation and cleavage
of the highly cross-linked peptidoglycan structure. A zinc ion is bound at the center of
the groove in an arrangement typical of zinc-dependent metalloenzymes. The impor-
tant role of the zinc ion is supported by the ﬁnding that mutation of all zinc-binding
residues abolished the activity of the amidase domain. The SH3b domain of LysGH15
was found to be structurally very similar to that of the lysostaphin homologue ALE-1.
FIG 3 Schematic representation of S. aureus peptidoglycan and LysK cleavage sites. The peptidoglycan
is made up of sugar strands consisting of two alternating units (N-acetylmuramic acid and
N-acetylglucosamine) and peptide linkers connecting these strands. Five units of glycine (Gly) act as a
cross-bridge between stem peptides.
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Nuclear magnetic resonance (NMR) titration experiments using the peptide “AGGGGG,”
mimicking the pentaglycine bridge of staphylococcal peptidoglycan, revealed the
interaction of this peptide with residues of the presumptive peptidoglycan-binding
groove of the SH3b domain albeit at a relatively low afﬁnity. Mutation of the respective
residues abolished the binding of the CBD to S. aureus peptidoglycan (91). Besides
LysGH15, another LysK homologue, named SAL-1, was recently described and exten-
sively characterized (137–139). This endolysin differs from LysK in only 3 amino acids;
however, it was claimed by those authors to exhibit higher activity against multiple S.
aureus strains than LysK (139). SAL-1 is the ﬁrst endolysin that has been intravenously
administered to humans (140), which is discussed in more detail below.
In Vivo Studies with LysK and Its Derivatives and Homologues
Although quantitative comparison of results between different laboratories is difﬁ-
cult, LysK and its homologues are among the most potent staphylococcal phage
endolysins described to date. In direct comparison with 7 endolysins from different
homology groups, LysK revealed the highest staphylolytic activity, as determined by
turbidity reduction assays, and also proved most effective at removing S. aureus
bioﬁlms from polystyrene surfaces (78). Furthermore, this endolysin has a broad
spectrum of activity, killing a variety of S. aureus strains, including MRSA, VRSA, and
teicoplanin-resistant strains; surface mutant strains; as well as coagulase-negative
staphylococci (78, 124, 141). In addition, LysK has been demonstrated to exhibit strong
synergy when applied in combination with lysostaphin, presumably due to the differ-
ent peptidoglycan cleavage sites of these two enzymes (102). All these properties make
LysK and its derivatives and close homologues highly interesting as potential anti-
staphylococcal therapeutics and have led researchers to investigate their efﬁcacy in
various in vivo models.
In a mouse model of systemic MRSA infection, which was part of the above-
mentioned comparative endolysin characterization, LysK (injected intraperitoneally 30
min after infection at 200 g/mouse) was one of the most effective enzymes, saving
100% of the animals from death. MRSA was not detected in the blood of any of the
LysK-treated mice at the conclusion of the experiment, but 67% of control animals
surviving after 48 h tested positive for bacteremia, with an average concentration in the
blood of 2.48 log CFU/ml (78).
Besides full-length LysK, the truncated construct CHAPK has also been shown to be
a potent antimicrobial both in vitro and in vivo. Its lytic spectrum is even broader than
that of LysK and, besides numerous species of Staphylococcus, includes members of the
genera Streptococcus, Micrococcus, Arthrobacter, Nesterenkonia, Carnobacterium, and
Leuconostoc. The active pH range of the enzyme is 6 to 11, with optimum activity at pH
9, and it shows activity at temperatures between 5 and 40°C, suggesting potential
applications in various ﬁelds such as medicine and food production (142). CHAPK also
proved effective at preventing S. aureus bioﬁlm formation and removing preformed
bioﬁlms from artiﬁcial surfaces (143). Bioﬁlms play an important role in bacterial
infections of both humans and animals and as a source of contamination in food
production and processing. Finally, nasal and oral administration of CHAPK to mice that
had been inoculated in the nostrils with S. aureus caused an effective reduction in
bacterial concentrations by 2 logs (144).
Similar to the full-length LysK endolysin, its close homologue LysGH15 has also been
evaluated in a mouse model of systemic MRSA infection. Mice infected intraperitoneally
with two times the minimum lethal dose of an MRSA strain were treated with different
concentrations of the endolysin injected via the same route at various time points after
infection. One hundred percent protection of the mice was achieved when the protein
was administered at 1 h postinfection at a concentration of 50 g/mouse. Numbers of
MRSA bacteria in the blood of mice treated with this dose were decreased by 2 log units
within 2.5 h, whereas those of control mice were increased to 107 CFU/ml (145).
Besides its in vivo efﬁcacy, LysGH15 was found to exhibit higher average in vitro activity
against a tested set of MRSA strains than against a selection of MSSA strains. Those
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authors hypothesized that this could be due to a tighter binding of LysGH15 to cell wall
structures predominantly present in strains with methicillin resistance (145).
SAL-1, the second well-characterized homologue of LysK, is derived from the
Staphylococcus phage SAP-1 (139). In an effort to develop this enzyme as a therapeutic
agent for human application, those authors demonstrated that a stabilizing formulation
containing poloxamer 188 and Ca ions increased its lytic activity against S. aureus
planktonic cells, encapsulated forms, and bioﬁlms in vitro. The intravenous administra-
tion of this preformulation, which was designated SAL200, to mice once a day for 3 days
after infection with MRSA signiﬁcantly reduced the mortality of the animals. Further-
more, no bacteria were recovered from blood and splenic tissue of SAL200-treated
mice, whereas concentrations between 105 and 107 CFU/ml were found in the control
groups (137). SAL200 is the ﬁrst endolysin-based therapeutic that underwent a good
laboratory practice (GLP)-compliant safety evaluation, including single- and repeated-
dose toxicity studies and central nervous system, respiratory, and cardiovascular func-
tion tests in rats and dogs (146). Rats tolerated repeated doses of 100 mg/kg over 4
weeks, and no signs of abnormal behavior or toxicity were observed. Two weeks of
repeated dosing showed no changes related to the treatment in dogs, including
changes in food consumption, body weight, electrocardiography, ophthalmology,
hematology, urinalysis, organ weight, or serum biochemistry. However, mild and
transient (i.e., lasting for 30 min to 1 h after injection) clinical signs such as irregular
respiration, subdued behavior, and vomiting were observed in dogs starting after 10
days of repeated administration. Upon further investigation, an immune response was
elicited after repeated exposure to the enzyme for 14 and 28 days in dogs and rats,
respectively, as measured by the presence of anti-SAL-1 antibodies. The exposed dogs
also showed a reduction in the level of blood C3 complement, considered represen-
tative of the complement system (146). It is unclear whether this response was due to
the enzyme itself or due to residual lipopolysaccharide endotoxin in the protein
preparation. Nonetheless, after the injection of SAL200, the symptoms were observed
only transiently and were considered mild (146). In a further safety and pharmacoki-
netic study conducted in monkeys, SAL200 was well tolerated and did not cause any
adverse effects when injected as a single dose (up to 80 mg/kg body weight) or as
multiple doses, up to 40 mg/kg per day (138). Most recently, SAL200 became the ﬁrst
endolysin-based drug applied to humans by intravenous infusion as part of a phase 1
clinical trial (140). Single ascending doses (up to 10 mg/kg) were applied to healthy
male volunteers, and pharmacokinetics, pharmacodynamics, and tolerance of the drug
candidate were evaluated. No serious adverse effects or clinically signiﬁcant values
were observed for any of the participants as a consequence of administration up to the
highest tested dose. Mild and temporarily observed effects included fatigue, headache,
rigors, and myalgia.
ENDOLYSIN PRODUCTION IN LACTIC ACID BACTERIA FOR FOOD SAFETY
APPLICATIONS
Besides its role as an infectious agent, S. aureus is also an important foodborne
pathogen. It causes food poisoning through the production of heat-stable enterotoxins
during growth in contaminated food products. When ingested, even in the absence of
the bacterium, these toxins cause classical symptoms of foodborne intoxication such as
vomiting and diarrhea (147, 148). The addition of puriﬁed endolysins to certain high-risk
food products is being discussed as one possibility to prevent the growth of pathogenic
organisms and thereby the production of toxins in food. An alternative approach is the
use of starter organisms used in the production of fermented food for the expression
and secretion of active endolysins into the product (93). Lactic acid bacteria have been
utilized for years in different food preservation and fermentation processes (149). Both
lactococci and lactobacilli have been characterized as probiotic bacteria, based on their
“generally recognized as safe” (GRAS) status, and they have been exploited for heter-
ologous protein production (150, 151). Furthermore, lactococci are found as commen-
sals in the gastrointestinal tract, oral cavity, and female reproductive tract. Lactococcus
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lactis in particular is a nonpathogenic, Gram-positive, spherical bacterium that has been
widely used by the food industry, e.g., in the production of fermented dairy products
(152). Also, biotechnology has widely used this bacterium as an expression system in
order to produce heterologous proteins on a large scale (153, 154). The Listeria phage
endolysins Ply118 and Ply511, which are an L-alanoyl–D-glutamate peptidase and an
N-acetylmuramoyl–L-alanine amidase, respectively, were the ﬁrst endolysins success-
fully produced and secreted by L. lactis. That study was conducted in an effort to
develop dairy starter strains with biopreservation properties for enhanced food safety
(111). Similarly, Ply511 and lysostaphin were produced and secreted in various different
lactic acid bacteria, one of which (a Lactobacillus plantarum strain secreting lysostaphin)
was able to reduce numbers of S. aureus bacteria by 7 log units in a coculture study
(155).
O’Flaherty and colleagues were the ﬁrst ones to produce a staphylococcal phage
endolysin (LysK) in L. lactis (124), using a nisin-inducible expression system (Fig. 4) (156),
in order to overcome solubility problems encountered when attempting expression in
Escherichia coli at that time. In this case, the active endolysin was not secreted, but its
staphylolytic activity was detected in lysates of the L. lactis culture (124). The crude
lysates caused a 99% reduction in numbers of MRSA bacteria within 1 h, demonstrating
that recombinantly produced LysK in L. lactis is able to eradicate live cells of pathogenic
staphylococci (124).
More recently, the same expression system was used for the production of the
staphylococcal phage endolysin LysH5 in L. lactis (157). In addition to the PnisA
promoter, various other constitutive and inducible lactococcal promoters were tested
in order to optimize production. As opposed to the previous study with LysK, a signal
peptide was fused to the LysH5 endolysin, which resulted in its secretion into the
culture supernatant (Fig. 4). However, secretion was found to occur with low efﬁciency,
and most of the protein was still found in the cellular fraction. In conclusion, the
production and secretion of recombinant endolysins in lactic acid bacteria could be a
FIG 4 Protein secretion pathway in the nisin-controlled gene expression system in L. lactis. After nisin is
detected by the sensor histidine kinase protein located in the membrane (NisK), autophosphorylation of
this protein occurs, followed by the transfer of its phosphatase group to the cytoplasmic response
regulator NisR. NisR, which is now activated, then activates transcription via the PnisA promoter, followed
by the production of a target protein, which in this case is a recombinant endolysin. Depending on the
presence or absence of a speciﬁc signal peptide, the protein either is secreted into the external medium
or accumulates in the cytoplasm.
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viable method to deliver the enzymes into food products, but the efﬁciency of the
expression and secretion systems still needs to be improved.
NANOTECHNOLOGY AS A NEW STRATEGY FOR ENDOLYSIN DELIVERY
Considering the continuous evolution of resistance mechanisms against multiple
commercial antibiotics, regimes of traditional therapies need to be overhauled and
developed into novel strategies (158). Nanoparticles (NPs) are now being used exten-
sively for the delivery of therapeutic agents such as anticancer drugs to eukaryotic cells
(159, 160), and they also offer possibilities to effectively target bacterial cells (161, 162).
Since surfaces of various NPs can be modiﬁed to allow conjugation with biological
molecules via different functional groups, these particles can be utilized as efﬁcient
vehicles that are able to deliver a predetermined amount of antibiotic molecules to the
target pathogens (163, 164).
Several research groups are now investigating nanotechnology-based methods to
design delivery vehicles for antibiotics and other antimicrobial compounds (159, 160).
Similarly, there are possibilities for engineering surfaces or interiors of NPs with
ﬂuorophores in order to achieve quantitative detection (165). By utilizing these prop-
erties in combination, NPs could be capable of improving diagnostics and the treat-
ment of bacterial infections at the same time (166, 167).
Aiming to increase therapeutic efﬁcacy, one or several morphological and antibac-
terial features of NPs can be exploited. This includes the application of NPs as (i)
membrane-penetrating agents in order to effectively transduce antimicrobials into
bacterial cells (168–171), (ii) drug-concentrating agents enabling polyvalent effects
through tight packing of antimicrobials on the NP surface (172, 173), and (iii)
attacking agents that are able to speciﬁcally act against biological targets, either
through inherent antimicrobial properties or through coupling with antimicrobial
agents (174–176).
Some NPs, such as those consisting of copper, silver, and selenium, have intrinsic
antimicrobial properties, which could possibly be further enhanced by combining or
coating them with more speciﬁc antibacterial agents, taking advantage of synergistic
effects (177, 178). For example, several reports described enhanced antimicrobial
effects of antibiotics against various bacterial pathogens, including S. aureus, when
used in combination with silver NPs (Fig. 5) (179–181). Besides NPs with intrinsic
antimicrobial properties, there are other types of NPs that can be used in therapeutic
applications that do not exhibit any antimicrobial effect themselves but are able to
enhance the effect of other therapeutic agents or approaches. Gold nanoparticles
(Au-NPs), for instance, are employed in several antimicrobial applications and have
been reported to enhance the killing efﬁcacy of antimycobacterial peptides (182).
There are various examples in the literature describing the conjugation or combined
application of phage endolysins or individual domains thereof with different types of
nanoparticles. The Listeria phage endolysin Ply500 is a reportedly strong antimicrobial
FIG 5 Schematic structure of an antibiotic-nanoparticle conjugate reacting with receptors within the
cytoplasmic membrane. Ag-NP, silver nanoparticle; ABX, any kind of natural, synthetic, or recombinant
antibiotic.
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agent that is active against strains of the foodborne pathogen Listeria monocytogenes
(183). A conjugate of Ply500 with silica nanoparticles (SNPs) retained the activity of
the endolysin and was able to reduce numbers of Listeria bacteria in suspension by
almost 5 log units within 24 h. A complete eradication (4-log reduction) of Listeria
bacteria was achieved on iceberg lettuce (184). Surprisingly, the conjugation of
SNPs with Ply500 signiﬁcantly enhanced the stability of the endolysin. When
incubated at 25°C for 15 days, the Ply500-SNP conjugates retained 90% of their
activity, whereas the unconjugated enzyme was completely inactivated over the
same period of time (184). In that same study, Ply500 was immobilized on edible
cross-linked starch NPs via maltose-binding protein (MBP). Both engineered Ply500-
MBP fusion proteins alone and the Ply500-MBP-NP conjugates caused a 2.5-log
reduction of the number of Listeria bacteria in suspension. These results demon-
strate that the immobilization of lytic enzymes on NPs can enhance protein stability
and thereby the efﬁcacy of the enzymes in food applications, where lytic activity
during extended periods of storage is desired. Similarly, the conjugation of SNPs
with LysK or other S. aureus-speciﬁc endolysins could improve the efﬁcacy of these
enzymes in certain niche applications.
Other nanotechnology-based approaches employ certain polymers as controlled
drug release vehicles, which are able to initiate a “burst response” triggered by
certain host- or pathogen-produced stimuli. These stimuli may include temperature
or pH changes; consequences of a host immune response, such as increased
cytokine concentrations (185, 186); and molecules released from infecting bacteria,
such as enzymes, secreted toxins, and signaling molecules (187–189). Various
polymers have been studied as potential drug release vehicles for research and
clinical purposes, including poly(N-isopropylacrylamide) (PNIPAM) (190), chitosan
(CS) (191, 192), fucoidan (F) (192), PLLs (193), and poly(lactic-co-glycolic acid) (PLGA)
(194). PNIPAM is a thermostatic polymer that is able to reversibly undergo a phase
transition at its lower critical solution temperature (LCST), which leads to water
expulsion, followed by a polymer volume change. By controlling the polymer
concentration as well as surfactant and copolymer concentrations, the LCST of
PNIPAM and the structures derived from this polymer (NPs, nanogels, and micelles,
etc.) can be manipulated and adjusted to a clinically relevant temperature, resulting
in a wide range of possible biomedical applications, such as wound healing, cell
cultivation, bioscaffolding, and cancer therapy (195–197). NPs of PNIPAM copoly-
merized with allylamine have been used for the controlled release of bacteriophage
K as an active antistaphylococcal agent, in which NP collapse was thermally
controlled (198).
More recently, that same group used PNIPAM NPs for the coadministration of the
endolysin construct CHAPK and lysostaphin via a thermally triggered release event.
Aiming to develop this system for the treatment of S. aureus skin infections, the
temperature at which the controlled expulsion of CHAPK and lysostaphin from the
polymer occurs was adjusted to 37°C, corresponding to the threshold temperature of
an infected wound in the skin. While no bacterial lysis in the presence of the NPs
occurred at 32°C (the temperature of healthy skin), numbers of S. aureus bacteria were
reduced by 4 log units when the temperature was increased to 37°C, owing to the
release of the active enzyme mix. CHAPK and lysostaphin were chosen for these
experiments due to their demonstrated synergistic effect when used in combination
(199).
The generation of complexes consisting of endolysins and cationic polymers (PLLs)
has also been reported as a possible way to produce antimicrobial agents with high
activity against the target bacteria and enhanced stability at both storage and physi-
ological temperatures. The stability of LysK in complexes with PLLs and their block
copolymers with polyethylene glycol (PEG) was improved by both hydrophobic and
electrostatic mechanisms (193). The stabilizing effect was attributed to enhanced
structural ordering and breaking of aggregates due to electrostatic interactions. In
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addition, the lytic activity of LysK increased 3- to 3.5-fold when complexed with cationic
polymers compared to the free form (193).
Another interesting NP-based approach relies on the thermal ablation of patho-
gens by Au-NPs functionalized with CBDs from endolysins instead of the antimi-
crobial properties of the endolysins themselves. The CBDs immobilized on the
surface of the Au-NPs ensure their speciﬁc binding to the surface of the target
pathogens. Once in the proximity of the bacteria, the NPs can be heated to high
temperatures by infrared (IR) irradiation to kill the organisms. This principle was
successfully demonstrated with Au-NPs functionalized with the CBD of PlyC, PlyCB,
which reduced numbers of streptococci by several log units upon IR irradiation,
while irradiation alone had only a minor effect (200). This approach may also be
extended to other bacterial genera such as staphylococci by using CBDs speciﬁc for
the target pathogen.
CONCLUDING REMARKS
Strains of pathogenic bacteria that are resistant to one or multiple antibiotics are
increasingly prevalent, and since this has become a problem of global signiﬁcance,
alternative solutions are urgently needed. Endolysins show great potential as a
possible replacement for or an addition to conventional antibiotics. Their high
antibacterial activity and speciﬁcity and the low chance of resistance development
make them promising candidates as antimicrobials against multiple bacterial patho-
gens and for various ﬁelds of application, including medicine, food safety, and
agriculture. Most staphylococcal phage endolysins show a broad activity spectrum
for the genus Staphylococcus. After the ﬁrst in vitro characterization of a puriﬁed
staphylococcal phage endolysin in the 1990s and the ﬁrst in vivo studies 1 decade
ago, research on these potent enzymes has intensiﬁed, and most recently, the ﬁrst
clinical study in humans was reported.
LysK and its close homologues LysGH15 and SAL-1 are among the best-studied
staphylococcal phage endolysins to date. Several attributes of these enzymes, including
their high staphylolytic activity; the presence of 2 catalytic domains, which further
reduces the chance of resistance formation; and the ﬁnding that they act synergistically
with other antimicrobials support their further exploitation as valuable and robust
antibacterial agents for the treatment of S. aureus infections. Moreover, enzymatic
activity and stability may be increased by the addition of low-cost additives such as
glycerol and calcium ions, and novel delivery strategies may further enhance the
efﬁcacy of these endolysins in various types of applications. The ability of lactic acid
bacteria to express and secrete functional endolysins opens new possibilities for
applications in food production and processing.
Furthermore, researchers have recently focused on the development of novel
nanotechnology-based delivery vehicles for antimicrobial agents, including phage
endolysins. Controlled-release systems, which allow the delivery of endolysins to
infection sites depending on parameters indicative of inﬂammation, may be of partic-
ular interest for future developments.
In conclusion, staphylococcal phage endolysins such as LysK and its derivatives hold
great promise for being used as novel therapeutic agents against infections by S. aureus
in the future, presenting several important advantages over traditional antibiotics. The
ﬁrst endolysin-based products have already hit the market, and in the light of ongoing
clinical trials, more developments can be expected in the near future.
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